Last reviewed · How we verify
combination therapy with MEKi.
combination therapy with MEKi. is a Small molecule drug developed by Mandana Kamgar, MD. It is currently in Phase 2 development. Also known as: mitogen-activated extracellular signal-regulated kinase inhibitor.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | combination therapy with MEKi. |
|---|---|
| Also known as | mitogen-activated extracellular signal-regulated kinase inhibitor |
| Sponsor | Mandana Kamgar, MD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients (PHASE2)
- Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
- A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy
- Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma (PHASE1)
- The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors (PHASE1)
- Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- combination therapy with MEKi. CI brief — competitive landscape report
- combination therapy with MEKi. updates RSS · CI watch RSS
- Mandana Kamgar, MD portfolio CI
Frequently asked questions about combination therapy with MEKi.
What is combination therapy with MEKi.?
Who makes combination therapy with MEKi.?
Is combination therapy with MEKi. also known as anything else?
What development phase is combination therapy with MEKi. in?
Related
- Manufacturer: Mandana Kamgar, MD — full pipeline
- Also known as: mitogen-activated extracellular signal-regulated kinase inhibitor
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing